Adjuvatis news
Interested in Adjuvatis’ drug formulation technology but want to learn more? Meet us at the Forum de la Recherche en Cancérologie organized by the Canceropole Rhone-Alpes CLARA, in April. Charlotte Primard, our CEO, will pitc
Poor water solubility is one of the most significant barrier limiting drug development. Indeed, more than 40% of compounds identified through combinatorial screening programs display poor aqueous solubility, which is associated with poor bioavailability, suboptimal dosing, etc.
Adjuvatis uses a safe-by-design technology that allows formulation of APIs with little or no solubility. Adjuvatis develop
FASTCURE is a consortium of experts for screening, identification and formulation of chemical compounds to combat SARS-CoV-2.
Drug repurposing can be a key strategy to fight against pathogens, especially when it comes as a rapid response to an emerging pathogen such as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) identified in Wuhan, China in January 2020, responsible for a worldwide pandemic, as declared by WHO on 11th March 2020.